Taylor & Francis Group
Browse
iceh_a_1714641_sm9243.docx (36.13 kB)

A post-marketing survey evaluating the safety and efficacy of a fixed-dose single-pill combination of cilnidipine and valsartan in patients with hypertension: Real-world JSH 2014 and 2019 implementations

Download (36.13 kB)
journal contribution
posted on 2020-01-22, 08:45 authored by Saori Matsuda, Shinobu Nagahama, Yoshiki Kurose, Maki Wakabayashi, Hitoshi Sugii, Tsukasa Teshima, Noriyuki Suzuki, Kazuomi Kario

: The home blood pressure control by a single-pill combination of cilnidipine and valsartan (HOPE-Combi) survey sought to evaluate the safety and efficacy of cilnidipine 10 mg/valsartan 80 mg single-pill combination (SPC of Cil/Val) treatment in patients with hypertension for over 12 months. Of 2622 subjects’ data; we analyzed 2572 cases for safety and 2372 cases for efficacy.

Adverse drug reaction (ADR) incidence rate was 3.77% (97 of 2572 patients). The frequency of ADRs did not differ between patients aged <75 years and those aged ≥75 years (3.70% vs. 3.93%, respectively); between patients with and without chronic liver disease (CLD; 6.44% vs. 3.54%, respectively); and between patients with and without chronic kidney disease (CKD; 5.26% vs. 3.59%, respectively). Office systolic blood pressure (BP) was reduced from 149.5 ± 19.6 mmHg to 133.5 ± 14.8 mmHg (−15.8 mmHg, P < .01); pulse rate was also reduced 75.5 ± 12.2 bpm to 73.5 ± 11.3 bpm (−1.8 bpm, P < .01) after 12 months.

: The SPC of Cil/Val was safe and effective in treating BP of hypertensive patients in real-world settings.

Funding

This work was supported by EA Pharma Co., Ltd. and MOCHIDA PHARMACEUTICAL CO., LTD.

History